HK1097256A1 - Pyrizdazine derivatives and their use as therapeutic agents - Google Patents
Pyrizdazine derivatives and their use as therapeutic agentsInfo
- Publication number
- HK1097256A1 HK1097256A1 HK07101166.9A HK07101166A HK1097256A1 HK 1097256 A1 HK1097256 A1 HK 1097256A1 HK 07101166 A HK07101166 A HK 07101166A HK 1097256 A1 HK1097256 A1 HK 1097256A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- pyrizdazine
- derivatives
- therapeutic agents
- therapeutic
- agents
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49109503P | 2003-07-30 | 2003-07-30 | |
US54681504P | 2004-02-23 | 2004-02-23 | |
US54689804P | 2004-02-23 | 2004-02-23 | |
US54678604P | 2004-02-23 | 2004-02-23 | |
US54682004P | 2004-02-23 | 2004-02-23 | |
US54693404P | 2004-02-23 | 2004-02-23 | |
US55341604P | 2004-03-16 | 2004-03-16 | |
US55340404P | 2004-03-16 | 2004-03-16 | |
US55349104P | 2004-03-16 | 2004-03-16 | |
US55344604P | 2004-03-16 | 2004-03-16 | |
US55340304P | 2004-03-16 | 2004-03-16 | |
PCT/US2004/024548 WO2005011655A2 (en) | 2003-07-30 | 2004-07-29 | Pyridazine derivatives and their use as therapeutic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1097256A1 true HK1097256A1 (en) | 2007-06-22 |
Family
ID=34120234
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK07101166.9A HK1097256A1 (en) | 2003-07-30 | 2007-02-01 | Pyrizdazine derivatives and their use as therapeutic agents |
HK16114675A HK1226399A1 (zh) | 2003-07-30 | 2016-12-23 | 噠嗪衍生物及其作爲治療劑的用途 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16114675A HK1226399A1 (zh) | 2003-07-30 | 2016-12-23 | 噠嗪衍生物及其作爲治療劑的用途 |
Country Status (23)
Country | Link |
---|---|
US (1) | US7335658B2 (zh) |
EP (3) | EP1648874B1 (zh) |
JP (1) | JP4808616B2 (zh) |
KR (1) | KR100934554B1 (zh) |
AR (1) | AR047557A1 (zh) |
AT (1) | ATE527242T1 (zh) |
AU (2) | AU2004261252C1 (zh) |
CA (1) | CA2533899C (zh) |
CY (1) | CY1112178T1 (zh) |
DK (1) | DK1648874T3 (zh) |
EC (1) | ECSP066313A (zh) |
ES (2) | ES2568769T3 (zh) |
HK (2) | HK1097256A1 (zh) |
HR (1) | HRP20110974T1 (zh) |
IL (1) | IL173395A (zh) |
MA (1) | MA28011A1 (zh) |
NO (1) | NO332822B1 (zh) |
NZ (1) | NZ545265A (zh) |
PL (1) | PL1648874T3 (zh) |
PT (1) | PT1648874E (zh) |
TN (1) | TNSN06034A1 (zh) |
TW (2) | TWI345974B (zh) |
WO (1) | WO2005011655A2 (zh) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040226056A1 (en) * | 1998-12-22 | 2004-11-11 | Myriad Genetics, Incorporated | Compositions and methods for treating neurological disorders and diseases |
US20050119251A1 (en) * | 2001-12-21 | 2005-06-02 | Jian-Min Fu | Nicotinamide derivatives and their use as therapeutic agents |
US7390813B1 (en) * | 2001-12-21 | 2008-06-24 | Xenon Pharmaceuticals Inc. | Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents |
US7759348B2 (en) * | 2003-07-30 | 2010-07-20 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
US7754711B2 (en) * | 2003-07-30 | 2010-07-13 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
JP4838128B2 (ja) * | 2003-07-30 | 2011-12-14 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ピペラジン誘導体および治療剤としてのその用途 |
EP1648874B1 (en) | 2003-07-30 | 2011-10-05 | Xenon Pharmaceuticals Inc. | Piperazine derivatives and their use as therapeutic agents |
US7514436B2 (en) * | 2003-07-30 | 2009-04-07 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
EP1737414A2 (en) * | 2004-01-23 | 2007-01-03 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments of inflammatory and neuropatic pain |
EP1814551A2 (en) * | 2004-09-20 | 2007-08-08 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
WO2006034440A2 (en) * | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
WO2006034446A2 (en) * | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Pyridine derivatives for inhibiting human stearoyl-coa-desaturase |
TW200626139A (en) * | 2004-09-20 | 2006-08-01 | Xenon Pharmaceuticals Inc | Heterocyclic derivatives and their use as therapeutic agents |
MX2007003332A (es) * | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa. |
TW200626572A (en) * | 2004-09-20 | 2006-08-01 | Xenon Pharmaceuticals Inc | Heterocyclic derivatives and their use as therapeutic agents |
AR051294A1 (es) | 2004-09-20 | 2007-01-03 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa |
BRPI0515483A (pt) | 2004-09-20 | 2008-07-22 | Xenon Pharmaceuticals Inc | derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase |
BRPI0515488A (pt) | 2004-09-20 | 2008-07-29 | Xenon Pharmaceuticals Inc | derivados de heterocìclicos e seu uso como agentes terapêuticos |
GT200600046A (es) * | 2005-02-09 | 2006-09-25 | Terapia de combinacion | |
WO2006125180A1 (en) * | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Piperazine derivatives and their uses as therapeutic agents |
WO2006125179A1 (en) * | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Tricyclic compounds and their uses as therapeutic agents |
WO2007044085A2 (en) * | 2005-05-19 | 2007-04-19 | Xenon Pharmaceuticals Inc. | Heteroaryl compounds and their uses as therapeutic agents |
EP2540296A1 (en) | 2005-06-03 | 2013-01-02 | Xenon Pharmaceuticals Inc. | Arminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
WO2007005763A2 (en) * | 2005-07-01 | 2007-01-11 | Novartis Ag | Combination of a renin inhibitor and an insulin secretion enhancer or an insulin sensitizer |
JO2769B1 (en) * | 2005-10-26 | 2014-03-15 | جانسين فارماسوتيكا ان. في | Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor |
WO2007071023A1 (en) * | 2005-12-20 | 2007-06-28 | Merck Frosst Canada Ltd. | Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
US7989461B2 (en) * | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
WO2007136746A2 (en) * | 2006-05-19 | 2007-11-29 | Xenon Pharmaceuticals Inc. | Macrocyclic compounds and their uses as stearoyl-coa desaturase |
KR101124070B1 (ko) | 2006-06-05 | 2012-04-12 | 제논 파마슈티칼스 인크. | 유기 화합물 |
JP2010501567A (ja) | 2006-08-24 | 2010-01-21 | ノバルティス アクチエンゲゼルシャフト | 代謝系、心血管系および他の障害の処置のためのステアロイル−CoA不飽和化酵素(SCD)阻害剤としての2−(ピラジン−2−イル)−チアゾールおよび2−(1H−ピラゾール−3−イル)チアゾール誘導体ならびに関連化合物 |
US8246433B2 (en) * | 2006-08-25 | 2012-08-21 | Alma Mater Sports, Llc | Team based fantasy sport contest |
WO2008056687A1 (fr) * | 2006-11-09 | 2008-05-15 | Daiichi Sankyo Company, Limited | Nouveau dérivé de spiropipéridine |
US20080182851A1 (en) * | 2006-11-20 | 2008-07-31 | Glenmark Pharmaceuticals S.A. | Acetylene derivatives as stearoyl coa desaturase inhibitors |
WO2008096746A1 (ja) | 2007-02-06 | 2008-08-14 | Takeda Pharmaceutical Company Limited | スピロ化合物およびその用途 |
JO2849B1 (en) | 2007-02-13 | 2015-03-15 | جانسين فارماسوتيكا ان. في | Dopamine 2 receptor antagonists are rapidly hydrolyzed |
US20100120669A1 (en) * | 2007-02-28 | 2010-05-13 | Anne Marie Jeanne Bouillot | Thiadiazole derivatives, inhibitors of stearoyl-coa desaturase |
KR20100016620A (ko) | 2007-04-23 | 2010-02-12 | 얀센 파마슈티카 엔.브이. | 속해리성 도파민 2 수용체 길항제로서의 4-알콕시피리다진 유도체 |
MX2009011416A (es) | 2007-04-23 | 2009-11-05 | Janssen Pharmaceutica Nv | Tia(di)azoles como antagonistas del receptor de dopamina 2 de disociacion rapida. |
MY148657A (en) * | 2007-04-27 | 2013-05-15 | Purdue Pharma Lp | Trpv1 antagonists and uses thereof |
CN101820757A (zh) | 2007-06-01 | 2010-09-01 | 普林斯顿大学托管委员会 | 通过调节宿主细胞代谢途径治疗病毒感染 |
WO2008157844A1 (en) | 2007-06-21 | 2008-12-24 | Forest Laboratories Holdings Limited | Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase |
EP2173711B1 (en) | 2007-08-08 | 2010-11-17 | Graceway Pharmaceuticals, LLC | Phenoxy-pyrrolidine derivative and its use and compositions |
AU2008302570B2 (en) * | 2007-09-20 | 2012-05-31 | Irm Llc | Compounds and compositions as modulators of GPR119 activity |
WO2009037542A2 (en) | 2007-09-20 | 2009-03-26 | Glenmark Pharmaceuticals, S.A. | Spirocyclic compounds as stearoyl coa desaturase inhibitors |
EP2231619B1 (en) * | 2007-12-11 | 2014-11-26 | F. Hoffmann-La Roche AG | Inhibitors of stearoyl-coa desaturase |
CN102171189B (zh) | 2008-07-31 | 2013-11-20 | 詹森药业有限公司 | 作为快速解离多巴胺2受体拮抗剂的哌嗪-1-基-三氟甲基取代的吡啶 |
ES2545864T3 (es) | 2009-02-17 | 2015-09-16 | Merck Canada Inc. | Nuevos compuestos espiránicos útiles como inhibidores de la estearoil-coenzima A delta-9 desaturasa |
WO2011011872A1 (en) | 2009-07-28 | 2011-02-03 | Merck Frosst Canada Ltd. | Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
WO2011014520A2 (en) | 2009-07-29 | 2011-02-03 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
WO2011030312A1 (en) | 2009-09-10 | 2011-03-17 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | NOVEL INHIBITORS OF STEAROYL-CoA-DESATURASE-1 AND THEIR USES |
JP2013507366A (ja) | 2009-10-09 | 2013-03-04 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Gpr119活性モジュレーターとしての化合物および組成物 |
US8394858B2 (en) | 2009-12-03 | 2013-03-12 | Novartis Ag | Cyclohexane derivatives and uses thereof |
US8697739B2 (en) | 2010-07-29 | 2014-04-15 | Novartis Ag | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof |
ME02609B (me) | 2011-06-22 | 2017-06-20 | Purdue Pharma Lp | TRPV1 ANTAGONISTI KOJI UKLJUČUJU DIHIDROKSI SUPSTITUENT l NJIHOVE UPOTREBE |
WO2013056148A2 (en) | 2011-10-15 | 2013-04-18 | Genentech, Inc. | Methods of using scd1 antagonists |
AU2013241854B2 (en) * | 2012-03-28 | 2017-11-02 | Intervet International B.V. | Heteroaryl compounds with cyclic bridging unit for use in the treatment helminth infection |
CN104768549A (zh) | 2012-05-22 | 2015-07-08 | 耶路撒冷希伯来大学的益生研究开发有限公司 | 未分化细胞的选择性抑制剂 |
WO2014052619A1 (en) | 2012-09-27 | 2014-04-03 | Irm Llc | Piperidine derivatives and compositions as modulators of gpr119 activity |
AU2016323992B2 (en) | 2015-09-16 | 2021-05-06 | Organovo, Inc. | Farnesoid X receptor agonists and uses thereof |
US11970486B2 (en) | 2016-10-24 | 2024-04-30 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
AU2018205275B2 (en) | 2017-01-06 | 2024-05-02 | Janssen Pharmaceutica Nv | Methods for the treatment of neurological disorders |
CN110637015B (zh) | 2017-03-15 | 2024-04-02 | 奥加诺沃公司 | 法尼醇x受体激动剂及其用途 |
CA3055990A1 (en) | 2017-03-15 | 2018-09-20 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
WO2019084157A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES THEREOF |
KR102325422B1 (ko) * | 2018-05-09 | 2021-11-11 | 주식회사 엘지화학 | 엔테로펩티다아제 억제 활성을 나타내는 신규 화합물 |
KR20210076910A (ko) | 2018-09-18 | 2021-06-24 | 메타크린, 인크. | 파르네소이드 x 수용체 효능제 및 그의 용도 |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US667452A (en) * | 1900-09-08 | 1901-02-05 | John A Hendrickson | Computing attachment for pumps. |
US2985657A (en) | 1959-10-12 | 1961-05-23 | Paul A J Janssen | 1-(aroylalkyl)-4-heterocyclylpiperazines |
DE2341925A1 (de) | 1973-08-20 | 1975-03-06 | Thomae Gmbh Dr K | Neue pyrimidinderivate und verfahren zu ihrer herstellung |
AT340933B (de) | 1973-08-20 | 1978-01-10 | Thomae Gmbh Dr K | Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze |
US5001125A (en) | 1984-03-26 | 1991-03-19 | Janssen Pharmaceutica N.V. | Anti-virally active pyridazinamines |
ES8802151A1 (es) | 1985-07-31 | 1988-04-01 | Janssen Pharmaceutica Nv | Un procedimiento para la preparacion de nuevos piridazinaminas. |
WO1988007527A1 (en) | 1987-04-03 | 1988-10-06 | The Upjohn Company | Amino-9,10-secosteroids |
CA1338012C (en) | 1987-04-27 | 1996-01-30 | John Michael Mccall | Pharmaceutically active amines |
MY104343A (en) | 1987-11-23 | 1994-03-31 | Janssen Pharmaceutica Nv | Novel pyridizinamine deravatives |
US4994456A (en) | 1989-03-01 | 1991-02-19 | Nisshin Flour Milling Co., Ltd. | Pyridinecarboxylic acid amide derivatives and pharmaceutical compositions comprising same |
IL96891A0 (en) | 1990-01-17 | 1992-03-29 | Merck Sharp & Dohme | Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them |
US5166147A (en) | 1990-07-09 | 1992-11-24 | The Du Pont Merck Pharmaceutical Company | 4-heteroaryl-and 4-aryl-1,4-dihydropyridine, derivatives with calcium agonist and alpha1 -antagonist activity |
GB9019143D0 (en) * | 1990-09-01 | 1990-10-17 | Bp Chem Int Ltd | Thixotropic compositions |
EP0520292A1 (de) | 1991-06-19 | 1992-12-30 | Hoechst Aktiengesellschaft | Chirale Azetidinon-Derivate und ihre Verwendung als Dotierstoffe in Flüssigkristallmischungen |
DE4302051A1 (de) | 1993-01-26 | 1994-07-28 | Thomae Gmbh Dr K | 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
PT876366E (pt) | 1996-01-15 | 2002-01-30 | Janssen Pharmaceutica Nv | Piridazinaminas inibidoras da angiogenese |
DE19614204A1 (de) * | 1996-04-10 | 1997-10-16 | Thomae Gmbh Dr K | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
JPH107572A (ja) | 1996-06-17 | 1998-01-13 | Sumitomo Pharmaceut Co Ltd | 腫瘍壊死因子産生阻害剤 |
AU8096798A (en) | 1997-06-27 | 1999-01-19 | Resolution Pharmaceuticals Inc. | Dopamine d4 receptor ligands |
AU743489B2 (en) | 1998-03-19 | 2002-01-24 | Pharmacia & Upjohn Company | 1,3,4-thiadiazoles useful for the treatment of CMV infections |
CA2348022A1 (en) | 1998-10-21 | 2000-04-27 | Takeda Chemical Industries, Ltd. | Condensed pyridazine derivatives, their production and use |
EP1126833A4 (en) | 1998-10-29 | 2004-09-08 | Trega Biosciences Inc | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES CONTAINING THESE DERIVATIVES |
EP1156045A4 (en) | 1999-01-28 | 2002-04-17 | Nippon Shinyaku Co Ltd | AMID DERIVATIVES AND DRUG COMPOSITIONS |
ES2209825T3 (es) | 1999-01-29 | 2004-07-01 | Abbott Laboratories | Derivados diazabiciclicos utiles como ligandos del receptor nicotinico de la acetilcolina. |
DK1035115T3 (da) | 1999-02-24 | 2005-01-24 | Hoffmann La Roche | 4-phenylpyridinderivater og anvendelse deraf som NK-1-receptorantagonister |
MXPA01010176A (es) | 1999-04-09 | 2002-03-27 | Meiji Seika Kaisha | Compuestos heterociclicos que contienen nitrogeno y compuestos de benzamida y farmacos que los contienen. |
JP3637961B2 (ja) * | 1999-09-16 | 2005-04-13 | 田辺製薬株式会社 | 芳香族含窒素六員環化合物 |
US6677452B1 (en) | 1999-09-30 | 2004-01-13 | Lion Bioscience Ag | Pyridine carboxamide or sulfonamide derivatives and combinatorial libraries thereof |
EP1243268A4 (en) | 1999-12-14 | 2003-05-21 | Nippon Shinyaku Co Ltd | MEDICINAL COMPOSITION |
US6987001B2 (en) | 2000-02-24 | 2006-01-17 | Xenon Pharmaceuticals Inc. | Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents |
BR0109188A (pt) | 2000-03-15 | 2003-03-18 | Warner Lambert Co | Diarilaminas 5-amida substituìdas como inibidores de mex |
US20020045613A1 (en) | 2000-04-27 | 2002-04-18 | Heinz Pauls | 1-aroyl-piperidinyl benzamidines |
GB0013383D0 (en) | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Therapeutic benzamide derivatives |
US7160878B2 (en) | 2000-07-27 | 2007-01-09 | Eli Lilly And Company | Substituted heterocyclic amides |
AU2001289457A1 (en) | 2000-09-26 | 2002-04-08 | Xenon Genetics Inc. | Methods and compositions employing a novel stearoyl-coa desaturase-hscd5 |
DE10060412A1 (de) | 2000-12-05 | 2002-06-06 | Bayer Ag | DELTA1-Pyrroline |
US20020169166A1 (en) | 2001-03-09 | 2002-11-14 | Cowart Marlon D. | Benzimidazoles that are useful in treating sexual dysfunction |
FR2823209B1 (fr) | 2001-04-04 | 2003-12-12 | Fournier Lab Sa | Nouvelles thiohydantoines et leur utilisation en therapeutique |
EP1389189A2 (en) * | 2001-05-22 | 2004-02-18 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues |
RU2285002C2 (ru) | 2001-06-15 | 2006-10-10 | Астеллас Фарма Инк. | Производное пиридина и фармацевтическая композиция на его основе |
JP4186518B2 (ja) * | 2001-06-15 | 2008-11-26 | アステラス製薬株式会社 | フェニルピリジン誘導体 |
US20050014942A1 (en) | 2001-10-30 | 2005-01-20 | Yasufumi Maruyama | Amide derivatives and drugs |
US6620811B2 (en) | 2001-11-19 | 2003-09-16 | Hoffmann-La Roche Inc. | Isonicotin- and nicotinamide derivatives of benzothiazoles |
CA2468716A1 (en) | 2001-11-28 | 2003-06-05 | Fujisawa Pharmaceutical Co., Ltd. | Heterocyclic amide compounds as apolipoprotein b inhibitors |
AU2002350172A1 (en) | 2001-12-07 | 2003-06-23 | Eli Lilly And Company | Substituted heterocyclic carboxamides with antithrombotic activity |
AU2003203148A1 (en) | 2002-02-05 | 2003-09-02 | High Point Pharmaceuticals, Llc | Novel aryl- and heteroarylpiperazines |
EP1485365B1 (en) | 2002-03-13 | 2008-05-14 | Janssen Pharmaceutica N.V. | Sulfonyl-derivatives as novel inhibitors of histone deacetylase |
IL164007A0 (en) | 2002-03-13 | 2005-12-18 | Janssen Pharmaceutica Nv | New inhibitors of histone deacetylase |
BR0307599A (pt) | 2002-03-13 | 2005-02-01 | Janssen Pharmaceutica Nv | Derivados de sulfonilamino como inibidores de histona deacetilase |
US7119203B2 (en) | 2002-04-25 | 2006-10-10 | Pharmacia Corporation | Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors |
AU2003251933A1 (en) | 2002-07-25 | 2004-02-16 | Wisconsin Alumni Research Foundation | Method for increasing insulin sensitivity and for treating and preventing type 2 diabetes |
JP2006505570A (ja) | 2002-10-17 | 2006-02-16 | アムジエン・インコーポレーテツド | ベンズイミダゾール誘導体およびそれのバニロイド受容体リガンドとしての使用 |
JP2004203871A (ja) | 2002-12-13 | 2004-07-22 | Yamanouchi Pharmaceut Co Ltd | 医薬組成物 |
ATE433967T1 (de) | 2003-01-17 | 2009-07-15 | Warner Lambert Co | 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation |
JP4838128B2 (ja) | 2003-07-30 | 2011-12-14 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ピペラジン誘導体および治療剤としてのその用途 |
EP1648874B1 (en) | 2003-07-30 | 2011-10-05 | Xenon Pharmaceuticals Inc. | Piperazine derivatives and their use as therapeutic agents |
US7514436B2 (en) * | 2003-07-30 | 2009-04-07 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
-
2004
- 2004-07-29 EP EP04779562A patent/EP1648874B1/en active Active
- 2004-07-29 WO PCT/US2004/024548 patent/WO2005011655A2/en active Application Filing
- 2004-07-29 TW TW093122736A patent/TWI345974B/zh not_active IP Right Cessation
- 2004-07-29 ES ES10184939.6T patent/ES2568769T3/es active Active
- 2004-07-29 AU AU2004261252A patent/AU2004261252C1/en not_active Ceased
- 2004-07-29 PT PT04779562T patent/PT1648874E/pt unknown
- 2004-07-29 CA CA2533899A patent/CA2533899C/en active Active
- 2004-07-29 TW TW099123172A patent/TW201038270A/zh unknown
- 2004-07-29 ES ES04779562T patent/ES2375134T3/es active Active
- 2004-07-29 AR ARP040102690A patent/AR047557A1/es not_active Application Discontinuation
- 2004-07-29 AT AT04779562T patent/ATE527242T1/de active
- 2004-07-29 PL PL04779562T patent/PL1648874T3/pl unknown
- 2004-07-29 JP JP2006522075A patent/JP4808616B2/ja not_active Expired - Fee Related
- 2004-07-29 US US10/901,563 patent/US7335658B2/en not_active Expired - Fee Related
- 2004-07-29 DK DK04779562.0T patent/DK1648874T3/da active
- 2004-07-29 EP EP16000190.5A patent/EP3042895A1/en not_active Withdrawn
- 2004-07-29 KR KR1020067002017A patent/KR100934554B1/ko not_active IP Right Cessation
- 2004-07-29 EP EP10184939.6A patent/EP2316827B1/en active Active
- 2004-07-29 NZ NZ545265A patent/NZ545265A/en not_active IP Right Cessation
-
2006
- 2006-01-25 EC EC2006006313A patent/ECSP066313A/es unknown
- 2006-01-26 IL IL173395A patent/IL173395A/en not_active IP Right Cessation
- 2006-01-27 TN TNP2006000034A patent/TNSN06034A1/en unknown
- 2006-02-27 MA MA28839A patent/MA28011A1/fr unknown
- 2006-02-28 NO NO20060981A patent/NO332822B1/no not_active IP Right Cessation
-
2007
- 2007-02-01 HK HK07101166.9A patent/HK1097256A1/xx not_active IP Right Cessation
-
2009
- 2009-05-05 AU AU2009201788A patent/AU2009201788B2/en not_active Ceased
-
2011
- 2011-12-28 HR HR20110974T patent/HRP20110974T1/hr unknown
- 2011-12-29 CY CY20111101290T patent/CY1112178T1/el unknown
-
2016
- 2016-12-23 HK HK16114675A patent/HK1226399A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1226399A1 (zh) | 噠嗪衍生物及其作爲治療劑的用途 | |
IL173398A0 (en) | Pyridyl derivatives and their use as therapeutic agents | |
GB0307918D0 (en) | Therapeutic use | |
GB0303910D0 (en) | Therapeutic agents | |
GB0308318D0 (en) | Therapeutic agents | |
TWI349551B (en) | Thiophenepyrimidinone derivatives and their use in therapy | |
GB0313250D0 (en) | Therapeutic agents | |
GB0310401D0 (en) | Therapeutic agent | |
GB0323378D0 (en) | Therapeutic agent | |
GB0314049D0 (en) | Therapeutic agents | |
GB0311859D0 (en) | Therapeutic agents | |
GB0311201D0 (en) | Therapeutic agents | |
GB0301350D0 (en) | Therapeutic agents | |
GB0207410D0 (en) | Compounds and their therapeutic use | |
TWI365187B (en) | 7-azaindoles and the use thereof as therapeutic agents | |
EP1701736A4 (en) | THERAPEUTIC AGENTS AND ITS USES | |
GB0304524D0 (en) | Therapeutic agents | |
GB0207409D0 (en) | Benzofuran-2H-3-one compounds and their therapeutic use | |
GB0307333D0 (en) | Therapeutic agent | |
GB0306444D0 (en) | Composition and its therapeutic use | |
IL165420A0 (en) | Piperazinylacylpiperidine derivatives their preparation and therapeutic use thereof | |
GB0303165D0 (en) | Therapeutic methods and compositions for use therein | |
GB0310251D0 (en) | Therapeutic methods and compositions for use therein | |
GB0326870D0 (en) | Therapeutic methods and compositions for use therein | |
GB0302801D0 (en) | Therapeutic methods and compositions for use therein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20170729 |